Form D · Biotechnology
Normunity Holding Company, LLC
Boston, MA · CIK 0001904252
Offering snapshot reported Jan 14, 2025 · SEC filing
- Reported sold
- $37.5M Offering amount: $75M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 10, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 14, 2025 | Initial | $37,500,000 | No comparison | 13 | SEC filing |
| Jan 13, 2022 | Initial | $45,863,302 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-535143
Source: Form D, filed Jan 14, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sakae Asanuma | Director |
| Darlene Deptula Hicks | Executive |
| Paulina Hill | Director |
| Rachel Humphrey | Director, Executive |
| Sara Nayeem | Director |
| David Parry | Director |
| Marie Claire Peakman | Director |
| Scott Phillips | Executive |
| Debanian Ray | Director |
| Timothy Shannon | Director |
| James Trenkle | Director |
| Yunxia Yang | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
One Beacon Street 15th Floor
Boston, MA, 02108
Boston, MA, 02108